TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must ≥ 18 years of age inclusive, at the time of signing the informed consent.~* Participants with severe hemophilia A (FVIII: C\<1%)~* PTPs (Previously treated patients) (≥150 ED (Exposure day)) on prophylaxis treatment before enrollment~* Participants who are immunocompetent. If human immunodeficiency virus (HIV) positive, cluster of differentiation 4 (CD4)+ lymphocyte count \>200/mm\*3~* Participants who are willing to complete an eDiary~* Male participants~* Capable of giving signed informed consent~Exclusion Criteria:~* Any other inherited or acquired bleeding disorder in addition to Hemophilia A.~* Platelet count \< 100,000/mm\*3~* Creatinine \> 2x upper limit of normal~* AST or ALT \> 5x upper limit of normal (AST: aspartate aminotransferase; ALT: alanine aminotransferase)~* The participant has a planned major surgery.~* The participant is currently participating in another investigational drug study, or has participated in a clinical study involving an investigational drug within 30 days of signing informed consent or previous treatment in a clinical phase III study with BAY 94-9027 (now marketed as Jivi).~* Current evidence (by central laboratory) or history of inhibitor to FVIII with a titer ≥ 0.6 Bethesda unit (BU).~* Known hypersensitivity to the drug substance, excipients, or mouse or hamster protein.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Severe hemophilia A patients (Type: OTHER): Prophylactic treatment regimens should be guided by clinical judgement based on individual patient characteristics and treatment response.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Patients already treated with Insuplant 400 IU/ml via a Medtronic Implantable System 2007~2. Glycosylated hemoglobin ≤9.0%~3. Patient showing a percentage of error at refill equal or below 20%~4. Patient undergoing NaOH rinse procedure of at least 10 minutes period with or without flush Or Patient being re-implanted with a new pump (first fill with insulin)~5. Signed informed consent form prior to enrolment~Exclusion criteria:~1. Pump life time \> 6 years~2. Pump battery voltage \< 2.6 volts~3. Pregnancy or childbearing potential without a medically approved form of birth control~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insuman Implantable (Type: EXPERIMENTAL): Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.
- Insuplant (Type: ACTIVE_COMPARATOR): Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Development of an Intervention to Reduce Heavy Drinking and Improve HIV Care Engagement Among Fisherfolk in Uganda

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* occupation of working in the fishing industry or industry supporting the fishing industry; HIV+; on ART for at least 1 month; missed one or more dose of ART in the prior 2 weeks; consume 5 or more drinks per occasion 2 or more times in the prior month or have an AUDIT-C score of 4 or greater; not planning to move from the area within the next 6 weeks; have their own mobile phone and can be reached via phone~Exclusion Criteria:~* currently receiving a majority of income for work via mobile money, does not speak Luganda or English, unable to read basic Luganda or English, occupation of boat or engine owner.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Kisoboka: structural and behavioral intervention (Type: EXPERIMENTAL): The KISOBOKA intervention adapts and combines a behavioral intervention with a structural component. The behavioral intervention component includes, alcohol screening, financial literacy training, and counseling and goal setting related to savings, alcohol use, and HIV care engagement. The structural intervention component changes the mode of work payment from cash to mobile money.
- Screening and Referral (Type: ACTIVE_COMPARATOR): Brief feedback on AUDIT-C score, referral for alcohol counseling, and briefly discussion of the importance of HIV care engagement and adherence.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 18 or over diagnosed with rheumatoid arthritis after the age of 16~* Active rheumatoid arthritis defined as: ≥4 swollen joints and ≥4 tender/painful joints (from 28 joint count) and either erythrocyte sedimentation rate ≥28 mm/h, or C-reactive protein ≥10 mg/L.~* Currently taking one of the following disease-modifying anti-rheumatic drugs: methotrexate, sulfasalazine, hydroxychloroquine or chloroquine.~* Patients without essential hypertension or with essential hypertension if their blood pressure is controlled (\<140/90 mmHg) with anti-hypertensive medications being stable at least 4 weeks prior to randomisation.~Exclusion Criteria:~* Females who are pregnant or breastfeeding.~* Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders~* History of liver problems that have required previous investigations~* Evidence of tuberculosis infection~* Conditions that preclude or render difficult the 24-hour ambulatory blood pressure monitoring technique.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dosing Regimen A (Type: EXPERIMENTAL): Oral treatment
- Dosing Regimen B (Type: PLACEBO_COMPARATOR): Oral treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Combination Therapy of Microneedling and Minoxidil in Androgenetic Alopecia of Indonesian Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Indonesian~* Age 18-59 years~* Diagnosis of androgenetic alopecia~* Hamilton-Norwood type III-IV~Exclusion Criteria:~* Use of minoxidil or finasteride topical 1 month prior~* Use of minoxidil or finasteride oral 1 month prior~* Skin infection in the treatment area~* Cosmetic procedures for the treatment of alopecia androgenetic such as platelet rich plasma, laser therapy,or microneedling 3 months prior~* History of keloid

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- Minoxidil 5% solution (Type: EXPERIMENTAL): Patients will receive minoxidil 5%, twice a day, for a total duration of 12 weeks.
- Combination therapy of microneedling and minoxidil 5% solution (Type: EXPERIMENTAL): Patients will receive a combination therapy of microneedling and minoxidil 5%. Minoxidil 5%, will be given twice a day for a total duration of 12 weeks. The microneedling treatment will be given every 4 weeks (week 0, week 4, week 8)for a total duration of 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Extension Study of AMX0035 in Patients With ALS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Completion of all visits in the randomized, double blind AMX0035 study. Subjects that receive tracheostomy or PAV during the course of the main study will still be followed as ITT until the week 24 visit before enrollment in the OLE.~2. Must enroll in the OLE within 28 days of the Week 24 visit of the main study.~3. Signed informed consent to enter the open label extension phase.~Exclusion Criteria:~1. Discontinued study drug prematurely in the double-blind phase of the study for reasons other than tracheostomy or PAV.~2. Exposure to or anticipated requirement for any disallowed medication listed below.~3. Any ongoing adverse events that in the opinion of the Site Investigator are clear contraindications to the study drug.~4. Unstable cardiac or other life-threatening disease emergent during the randomized, double blind study~5. Any major medical condition that in the opinion of the Site Investigator would interfere with the study and place the subject at increased risk.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMX0035 (Type: EXPERIMENTAL): AMX0035 twice daily--a combination therapeutic including 3 gram of Phenylbutyrate and 1g TUDCA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Testing the Effect of the Youth Mindful Awareness Program on Negative Affect

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ages 12- to 17-years-old~* has access to a smartphone, tablet, or other mobile device on which they can access the mindfulness app and complete EMA reports. Youth without a device will be provided with one for their time in the study.~Exclusion Criteria:~* current DSM5 diagnosis of an anxiety or depressive disorder with significant clinical impairment~* current alcohol or substance use disorder; currently suicidal~* lifetime diagnosis of bipolar disorder, schizophrenia, autism, conduct disorder, or developmental delay~* reading level below 4th grade~* not English speaking at a level that would allow them to participate in the intervention and assessments.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Mindfulness (Type: EXPERIMENTAL): Internet-based, coached Mindfulness Program. Nine weekly coached sessions with practice exercises between sessions.
- Control (Type: NO_INTERVENTION): Participants in this arm are randomly assigned to an assessment-only, no intervention control condition.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Outpatients 18 years of age and older.~2. Patients with essential hypertension.~Exclusion Criteria:~Severe hypertension, Current diagnosis of heart failure, History or evidence of a secondary form of hypertension, Participation in any investigational drug study within one month of planned participation,~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients ≥ 18 years of age.~* Rheumatoid arthritis of ≤ 2 years duration.~* Disease Activity Score 28 (DAS28) \> 3.2.~* Swollen joint count (SJC) ≥ 4 of 66 joints, tender joint count (TJC) ≥ 6 of 68 joints.~* Rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) positive (if RF and anti-CCP negative \> 1 erosion required at screening).~* Erythrocyte sedimentation rate (ESR) ≥ 28 mm/h or C-reactive protein (CRP) ≥ 10 mg/L at screening.~Exclusion Criteria:~* Previous treatment with tocilizumab.~* Previous treatment with methotrexate or biologic agent.~* Rheumatic autoimmune disease other than rheumatoid arthritis (RA).~* History of or current inflammatory joint disease other than RA.~* Functional class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in RA.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- (A) Tocilizumab 8 mg/kg + placebo to methotrexate (Type: EXPERIMENTAL): Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.
- (B) Tocilizumab 8 mg/kg + methotrexate (Type: EXPERIMENTAL): Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.
- (C) Tocilizumab 4 mg/kg + methotrexate (Type: EXPERIMENTAL): Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.
- (D) Placebo to tocilizumab + methotrexate (Type: ACTIVE_COMPARATOR): Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Type 2 diabetes~* Age ≥30 and ≤80~* Currently treated with two classes of oral glucose-lowering therapy (given either as separate or combined medications), that do not include a DPP4-inhibitor, a SGLT2-inhibitor or a thiazolidinedione.~* Diabetes duration ≥12months~* No change in diabetes treatment (new treatments or dose change) within previous 3 months~* HbA1c \> 58mmol/mol (7.5%) and ≤110mmol/mol (12.2%) - confirmed at screening visit~* eGFR ≥ 60mls/min/1.73m² - confirmed at screening visit~* Able and willing to give informed consent~Exclusion Criteria:~* Changes in glucose-lowering therapy or dose within last 3 months~* HbA1c ≤ 58mmol/mol (7.5%) or \>110mmol/mol (12.2%)~* eGFR \<60mls/min/1.73m².~* Diabetes duration \<12 months~* ALT \>2.5 x upper limit of the assay normal range or known liver disease, specifically \>30 μmol/L that is associated with other evidence of liver failure.~* Insulin treated within the last 12 months~* Limb ischaemia shown by absence of both pulses in one or both feet.~* Currently treated with corticosteroids~* Currently treated with rifampicin, gemfibrozil, phenytoin and carbamazepine~* Active infection (any infection requiring antibiotics at present)~* Foot ulcer requiring antibiotics within previous three months~* Recent (within 3 months) significant surgery or planned surgery (excluding minor procedures)~* Acute cardiovascular episode (angina, myocardial infarction, stroke, transient ischemic episode) occurring within the previous 3 months~* History of heart failure~* Current use of loop diuretic therapy (Furosemide or Bumetanide)~* History of bladder carcinoma~* Current/ongoing investigation for macroscopic haematuria~* History of Diabetic Ketoacidosis~* History of pancreatitis~* Pregnant, breastfeeding or planning a pregnancy over the study period~* Concurrent Participation on another Clinical Trial of an Investigational Medicinal Product, where the IMP is currently being taken, or without sufficient washout period\* and without consultation with the CTIMP research team.~* Unable or unwilling to give informed consent~  * Sufficient washout period = five times the half-life of the IMP / potential IMP if involving a placebo / longest half-life if a trial includes more than one drug

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin - DPP4i (Type: EXPERIMENTAL): None
- Canagliflozin - SGLT2i (Type: EXPERIMENTAL): None
- Pioglitazone - TZD (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Capacity to consent and wish to participate in the study, documented by signing the specific informed consent form (ICF) of the study.~* Age of 18 years or older.~* Pregnancy documented by urine or blood examination or ultrasound.~* Gestational age of 14 to 30 weeks calculated by ultrasound, obstetric examination or date of last menstruation, depending on what is considered to be more exact by the medical investigator.~* HIV infection documented by two serological tests using different methods or analysis of HIV viral load with a positive result.~* No use of antiretroviral drugs at the time of diagnosis of pregnancy (previous prophylaxis and treatment are allowed).~* Intention to continue the treatment of the study for at least 6 weeks after delivery.~Exclusion Criteria:~* History of hypersensitivity to lopinavir or ritonavir.~* Need for the concomitant use of contraindicated drugs in combination with lopinavir/ritonavir.~* Any condition that, in the opinion of the medical researchers, impairs the participation in and fulfillment of the procedures of the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Active disease (inflammatory signs, erythrocyte sedimentation rate \[ESR\], C-reactive protein \[CRP\])~* Stable condition~* Stable basic treatments~* Morning stiffness on previous treatment with standard prednisone (below or equal to 10 mg per day) greater than or equal to (\>/=) 45 minutes~Exclusion Criteria:~* All contra-indications for glucocorticoids~* Pregnancy~* Concomitant treatment with biologics~* Intra-articular injections or synovectomy within the previous 4 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- MR Prednisone (Type: EXPERIMENTAL): Participants will receive MR prednisone at bed time and placebo matching to IR prednisone in the morning. Total duration of double blind treatment will be 12 weeks.
- IR Prednisone (Type: ACTIVE_COMPARATOR): Participants will receive IR prednisone in the morning and placebo matching to MR prednisone at bed time. Total duration of double blind treatment will be 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete